LY2624587 potently blocks SDF-1 binding to CXCR4, inhibits SDF-1/CXCR4 mediated cell signaling including ERK and AKT activation, induces cell surface receptor internalization, and induces dose-dependent cell death in vitro and in vivo in human hematologic cancer cells. Here, CXCL12 is linked to hematopoietic and lymphoid cell neoplasm.